ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate

ClinicalTrials.gov ID: NCT00298987

Public ClinicalTrials.gov record NCT00298987. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 9:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Study of Dasatinib (BMS-354825) in Subjects With Chronic Myelogenous Leukemia With Accelerated or Myeloid or Lymphoid Blast Phase or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant to or Intolerant of Imatinib Mesylate

Study identification

NCT ID
NCT00298987
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
400 participants

Conditions and interventions

Interventions

  • Dasatinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2006
Primary completion
May 31, 2007
Completion
May 31, 2007
Last update posted
Feb 7, 2010

2006 – 2007

United States locations

U.S. sites
30
U.S. states
21
U.S. cities
30
Facility City State ZIP Site status
Local Institution Corona California
Local Institution Aurora Colorado
Local Institution Colorado Springs Colorado
Local Institution Waterford Connecticut
Local Institution Daytona Beach Florida
Local Institution Jupiter Florida
Local Institution Atlanta Georgia
Local Institution Lawrenceville Georgia
Local Institution Beach Grove Indiana
Local Institution Indianapolis Indiana
Local Institution Iowa City Iowa
Local Institution Kansas City Kansas
Local Institution Salina Kansas
Local Institution Lexington Kentucky
Local Institution Louisville Kentucky
Local Institution Boston Massachusetts
Local Institution Ann Arbor Michigan
Local Institution Detroit Michigan
Local Institution Santa Fe New Mexico
Local Institution New York New York
Local Institution Cincinnati Ohio
Local Institution Cleveland Ohio
Local Institution Lawton Oklahoma
Local Institution Tulsa Oklahoma
Local Institution Portland Oregon
Local Institution Providence Rhode Island
Local Institution Charleston South Carolina
Local Institution Chattanooga Tennessee
Local Institution Spokane Washington
Local Institution Sheboygan Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00298987, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 7, 2010 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00298987 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →